Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the European Patent Office has granted the Company the patent titled “Methods and Compositions for Treating NAFLD, Hepatic Steatosis, and Sequelae Thereof.” This patent was previously granted to Oramed in the U.S. and is pending in several other major markets.

Oramed recently announced 100% enrollment in its Phase 2 trial which is assessing the safety and potential efficacy of its oral insulin ORMD-0801 in type 2 diabetes patients with non-alcoholic steatohepatitis (NASH). Data from a prior pilot study of ORMD-0801 in this indication showed a reduction in liver fat content.

The global market for drugs to treat NASH is expected to reach $84 billion by 2029, according to a publication by Research and Markets on the Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market.

Oramed ’s Diabetes Market Survey, carried out by IQVIA, shows strong interest for ORMD-0801 oral insulin candidate from physicians. 76 percent of the physicians responded that they “definitely would” or “probably would” prescribe it for Type 2 diabetes patients, with only 2 percent responding that they “probably would not” or “definitely would not prescribe it”. Overall, health care providers were receptive to prescribing oral insulin, if approved, and the sentiment for ORMD-0801 was very positive. Some potential benefits expressed by the physicians include less possibility of hypoglycemia or weight gain and the benefit of not using needles.

Oramed announced the appointment of Yadin Rozov to its Board of Directors effective April 1, 2022. Mr. Rozov is an investment professional with over twenty years of experience in capital markets, corporate finance, investment banking, and investment management with substantial experience in corporate strategy and governance. He is the founder and Managing Partner of Terrace Edge Ventures LLC, a financial advisory firm.

About NASH

Non-alcoholic steatohepatitis (NASH) is a serious, progressive liver disease caused by a buildup of fat in the liver and accompanied by inflammation, liver cell damage, and in some cases, scarring of the liver. Over time, NASH may progress to cirrhosis, liver cancer, liver failure, and even death. Currently, no pharmacotherapy is globally approved for the treatment of NASH, and people with NASH are left with very few treatment options.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 trials and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).

Source: Oramed April 5, 2022 https://www.oramed.com/